Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$370.1 million.

  • Cue Biopharma's Retained Earnings fell 1133.77% to -$370.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$370.1 million, marking a year-over-year decrease of 1133.77%. This contributed to the annual value of -$341.9 million for FY2024, which is 1350.44% down from last year.
  • As of Q3 2025, Cue Biopharma's Retained Earnings stood at -$370.1 million, which was down 1133.77% from -$362.6 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Retained Earnings ranged from a high of -$165.8 million in Q1 2021 and a low of -$370.1 million during Q3 2025
  • Its 5-year average for Retained Earnings is -$272.6 million, with a median of -$276.8 million in 2023.
  • As far as peak fluctuations go, Cue Biopharma's Retained Earnings tumbled by 3665.74% in 2021, and later crashed by 1133.77% in 2025.
  • Over the past 5 years, Cue Biopharma's Retained Earnings (Quarter) stood at -$197.4 million in 2021, then decreased by 26.85% to -$250.5 million in 2022, then fell by 20.26% to -$301.2 million in 2023, then fell by 13.5% to -$341.9 million in 2024, then dropped by 8.25% to -$370.1 million in 2025.
  • Its Retained Earnings was -$370.1 million in Q3 2025, compared to -$362.6 million in Q2 2025 and -$354.1 million in Q1 2025.